Transfusion-associated Chagas disease (American trypanosomiasis) in Mexico: implications for transfusion medicine in the United States.

BACKGROUND: Trypanosoma cruzi, the protozoan cause of Chagas disease, causes life-long infection and is easily transmitted by blood transfusion. Our goals were to determine the prevalence of Chagas disease among donors in five Mexican blood banks, to look for evidence of transmission of T. cruzi by transfusion, and to evaluate two serologic assays for Chagas disease. STUDY DESIGN AND METHODS: Blood samples from donors were tested initially with the Abbott Chagas EIA or the Meridian Chagas' IgG ELISA. Samples giving readings that were at least 50% of the cutoffs were run in a confirmatory radioimmune precipitation assay (RIPA), as were samples from recipients of blood products from RIPA-positive donors. RESULTS: The overall prevalence of Chagas disease was 1/133 (55/7,296; 0.75%). In addition, 4 of 9 surviving recipients of blood products from T. cruzi-infected donors were in turn infected. Using the manufacturers' recommended cutoffs, the sensitivity and specificity of the Abbott test were 92.0% (23/25) and 99.8% (2,865/2,872) respectively, and the corresponding values for the Meridian assay were 70.0% (21/30) and 100.0% (4,369/4,369). CONCLUSIONS: These findings indicate clearly that transfusion-associated transmission of T. cruzi is occurring in the study areas. Serologic testing of blood donors for Chagas disease should be performed there and in the rest of Mexico. The two screening assays evaluated may lack the accuracy necessary for blood donor testing when used as suggested by the manufacturers.

Bases para el uso combinado de los interferones y de los retinoides en oncología clínica / Basis for the combined use of interferon and retinoid in clinical oncology

El acido retinoico y el interferón alfa tienen actividad limitada en el tratamiento de cáncer avanzado. La información obtenida de los cultivos celulares indican que, en combinación, estos agentes tienen incremento de la actividad biológica modulando el crecimiento y la diferenciación en un número de tipos celulares malignos. Trabajos clínicos recientes sobre el tratamiento de algunos carcinomas avanzados de células escamosas informan actividad terapéutica con este régimen. Este artículo revisa los datos preclínicos obtenidos al evaluar el ácido retinoico en combinación con interferones

Estudio de factibilidad: ácido 13-cisretinoico, interferón Ó-2a y radioterapia concurrentes en el tratamiento de 23 pacientes con carcinoma epidermoide cervicouterino avanzado / Factibility study: acid 13-cis retinoic, interferon Ó-2a and radiotherapy concurrents in the treatment of 23 patients with advanced, epidermoid, cervicouterine carcinoma

Se confirma la importante actividad terapéutica de 13.cRA y del IFNÓ-2a en el carcinoma de células escamosas del cervix sin tratamiento previo. Un resultado inesperado fue la toxicidad temprana de los agentes biológicos sobre la mucosa del colon cuando se combinan con radioterapia